Expanding Phase III Study of Tyroserleutide for Injection
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial.
Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be
randomized in a 1:1 ratio to 1 of the 2 treatment groups：6mg/d Tyroserleutide (injection), or
placebo